• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过秩加权平均治疗效果评估治疗优先级规则

Evaluating Treatment Prioritization Rules via Rank-Weighted Average Treatment Effects.

作者信息

Yadlowsky Steve, Fleming Scott, Shah Nigam, Brunskill Emma, Wager Stefan

机构信息

Google DeepMind.

Department of Biomedical Data Science, Stanford University.

出版信息

J Am Stat Assoc. 2025;120(549):38-51. doi: 10.1080/01621459.2024.2393466. Epub 2024 Oct 11.

DOI:10.1080/01621459.2024.2393466
PMID:40248684
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12002561/
Abstract

There are a number of available methods for selecting whom to prioritize for treatment, including ones based on treatment effect estimation, risk scoring, and hand-crafted rules. We propose rank-weighted average treatment effect (RATE) metrics as a simple and general family of metrics for comparing and testing the quality of treatment prioritization rules. RATE metrics are agnostic as to how the prioritization rules were derived, and only assess how well they identify individuals that benefit the most from treatment. We define a family of RATE estimators and prove a central limit theorem that enables asymptotically exact inference in a wide variety of randomized and observational study settings. RATE metrics subsume a number of existing metrics, including the Qini coefficient, and our analysis directly yields inference methods for these metrics. We showcase RATE in the context of a number of applications, including optimal targeting of aspirin to stroke patients.

摘要

有多种方法可用于选择治疗的优先对象,包括基于治疗效果估计、风险评分和人工制定规则的方法。我们提出了排名加权平均治疗效果(RATE)指标,作为用于比较和测试治疗优先规则质量的一个简单且通用的指标家族。RATE指标对于优先规则的推导方式不做假设,仅评估它们识别出从治疗中获益最大个体的能力。我们定义了一个RATE估计量家族,并证明了一个中心极限定理,该定理能够在各种随机和观察性研究环境中进行渐近精确推断。RATE指标包含了许多现有指标,包括基尼系数,并且我们的分析直接得出了这些指标的推断方法。我们在包括阿司匹林对中风患者的最佳靶向治疗等多个应用场景中展示了RATE指标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa4b/12002561/dbf4f9e21981/nihms-2019256-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa4b/12002561/53671b7e5ef3/nihms-2019256-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa4b/12002561/aeb382e287cf/nihms-2019256-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa4b/12002561/50233d174b34/nihms-2019256-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa4b/12002561/f688b89a69fa/nihms-2019256-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa4b/12002561/dbf4f9e21981/nihms-2019256-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa4b/12002561/53671b7e5ef3/nihms-2019256-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa4b/12002561/aeb382e287cf/nihms-2019256-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa4b/12002561/50233d174b34/nihms-2019256-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa4b/12002561/f688b89a69fa/nihms-2019256-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa4b/12002561/dbf4f9e21981/nihms-2019256-f0005.jpg

相似文献

1
Evaluating Treatment Prioritization Rules via Rank-Weighted Average Treatment Effects.通过秩加权平均治疗效果评估治疗优先级规则
J Am Stat Assoc. 2025;120(549):38-51. doi: 10.1080/01621459.2024.2393466. Epub 2024 Oct 11.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
Efficient augmentation and relaxation learning for individualized treatment rules using observational data.利用观测数据进行个性化治疗规则的高效增强与松弛学习。
J Mach Learn Res. 2019;20.
4
Optimal individualized decision rules using instrumental variable methods.使用工具变量法的最优个体化决策规则。
J Am Stat Assoc. 2021;116(533):174-191. doi: 10.1080/01621459.2020.1745814. Epub 2020 May 12.
5
Resampling-based confidence intervals for model-free robust inference on optimal treatment regimes.基于重抽样的无模型稳健推断最优治疗方案的置信区间。
Biometrics. 2021 Jun;77(2):465-476. doi: 10.1111/biom.13337. Epub 2020 Aug 21.
6
Relative contrast estimation and inference for treatment recommendation.相对对比度估计与推荐治疗的推断。
Biometrics. 2023 Dec;79(4):2920-2932. doi: 10.1111/biom.13826. Epub 2023 Feb 7.
7
Targeted learning ensembles for optimal individualized treatment rules with time-to-event outcomes.用于具有事件发生时间结局的最优个体化治疗规则的靶向学习集成方法。
Biometrika. 2018 Sep;105(3):723-738. doi: 10.1093/biomet/asy017. Epub 2018 May 7.
8
Performance and estimation of the true error rate of classification rules built with additional information. An application to a cancer trial.利用额外信息构建的分类规则的性能及真实错误率估计。在癌症试验中的应用。
Stat Appl Genet Mol Biol. 2013 Oct 1;12(5):583-602. doi: 10.1515/sagmb-2012-0037.
9
Nonparametric inverse-probability-weighted estimators based on the highly adaptive lasso.基于高度自适应 lasso 的非参数逆概率加权估计量。
Biometrics. 2023 Jun;79(2):1029-1041. doi: 10.1111/biom.13719. Epub 2022 Jul 27.
10
Bayesian inference for optimal dynamic treatment regimes in practice.贝叶斯推断在实践中最优动态治疗方案的应用。
Int J Biostat. 2023 May 17;19(2):309-331. doi: 10.1515/ijb-2022-0073. eCollection 2023 Nov 1.

引用本文的文献

1
A Risk Stratification Model for Predicting Benefits of Intensive Blood Pressure Treatment: Analysis of the Systolic Blood Pressure Intervention Trial.一种用于预测强化血压治疗益处的风险分层模型:收缩压干预试验分析
J Clin Hypertens (Greenwich). 2025 Aug;27(8):e70098. doi: 10.1111/jch.70098.
2
Predictive Modeling of Heterogeneous Treatment Effects in RCTs: A Scoping Review.随机对照试验中异质性治疗效果的预测建模:一项范围综述
JAMA Netw Open. 2025 Jul 1;8(7):e2522390. doi: 10.1001/jamanetworkopen.2025.22390.
3
Understanding the causal effects and heterogeneity between metabolic syndrome and lung function: a nationwide prospective cohort study in China.

本文引用的文献

1
Individualising intensive systolic blood pressure reduction in hypertension using computational trial phenomaps and machine learning: a post-hoc analysis of randomised clinical trials.使用计算试验表型图谱和机器学习对高血压患者进行个体化强化收缩压降低治疗:随机临床试验的事后分析。
Lancet Digit Health. 2022 Nov;4(11):e796-e805. doi: 10.1016/S2589-7500(22)00170-4.
2
Primary stroke prevention worldwide: translating evidence into action.全球首发卒中预防:将证据转化为行动。
Lancet Public Health. 2022 Jan;7(1):e74-e85. doi: 10.1016/S2468-2667(21)00230-9. Epub 2021 Oct 29.
3
Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.
了解代谢综合征与肺功能之间的因果关系及异质性:一项中国全国性前瞻性队列研究。
Diabetol Metab Syndr. 2025 Jul 2;17(1):248. doi: 10.1186/s13098-025-01821-6.
4
Two-step pragmatic subgroup discovery for heterogeneous treatment effects analyses: perspectives toward enhanced interpretability.用于异质性治疗效果分析的两步实用亚组发现:增强可解释性的视角
Eur J Epidemiol. 2025 Feb;40(2):141-150. doi: 10.1007/s10654-025-01215-y. Epub 2025 Mar 4.
5
Potential clinical impact of predictive modeling of heterogeneous treatment effects: scoping review of the impact of the PATH Statement.异质性治疗效果预测模型的潜在临床影响:对PATH声明影响的范围综述
medRxiv. 2025 Feb 21:2024.05.06.24306774. doi: 10.1101/2024.05.06.24306774.
1990—2019年全球、区域和国家的卒中负担及其风险因素:全球疾病负担研究2019的系统分析
Lancet Neurol. 2021 Oct;20(10):795-820. doi: 10.1016/S1474-4422(21)00252-0. Epub 2021 Sep 3.
4
The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement.预测治疗效果异质性的方法(PATH)声明。
Ann Intern Med. 2020 Jan 7;172(1):35-45. doi: 10.7326/M18-3667. Epub 2019 Nov 12.
5
Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.急性缺血性脑卒中患者早期管理指南:2018 年急性缺血性脑卒中早期管理指南的更新:美国心脏协会/美国卒中协会发布的医疗保健专业人员指南。
Stroke. 2019 Dec;50(12):e344-e418. doi: 10.1161/STR.0000000000000211. Epub 2019 Oct 30.
6
Metalearners for estimating heterogeneous treatment effects using machine learning.使用机器学习估计异质处理效应的元学习器。
Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4156-4165. doi: 10.1073/pnas.1804597116. Epub 2019 Feb 15.
7
Hypertension-A Public Health Challenge of Global Proportions.高血压——一项全球性的公共卫生挑战。
JAMA. 2018 Nov 6;320(17):1757-1759. doi: 10.1001/jama.2018.16760.
8
Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From ACCORD BP and SPRINT.强化收缩压降压治疗对标准血糖控制的 2 型糖尿病患者及无糖尿病患者心血管事件和死亡率的影响:来自 ACCORD BP 和 SPRINT 的结果再分析。
J Am Heart Assoc. 2018 Sep 18;7(18):e009326. doi: 10.1161/JAHA.118.009326.
9
Clinical Implications of Revised Pooled Cohort Equations for Estimating Atherosclerotic Cardiovascular Disease Risk.修订后的汇总队列方程在估计动脉粥样硬化性心血管疾病风险中的临床意义。
Ann Intern Med. 2018 Jul 3;169(1):20-29. doi: 10.7326/M17-3011. Epub 2018 Jun 5.
10
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.2017美国心脏病学会/美国心脏协会/美国医师协会/美国心脏病学学会/美国预防医学学院/美国老年病学会/美国药学协会/美国血液学会/美国预防医学学会/美国医学协会/美国初级保健医师学会成人高血压预防、检测、评估和管理指南:美国心脏病学会/美国心脏协会临床实践指南工作组报告
J Am Coll Cardiol. 2018 May 15;71(19):e127-e248. doi: 10.1016/j.jacc.2017.11.006. Epub 2017 Nov 13.